Operational Footprint (as of October 1, 2026)

  • Total Healthcare Facilities: 56 facilities
  • Total Capacity Beds: 6,374
  • Operational Beds: 6,119
  • India Facilities: 21 Hospitals and Heart Centres (5,624 beds), 20 Clinics and Dialysis Centres (0 beds)
  • International Facilities: Cayman Islands (2 facilities, 165 beds), United Kingdom (13 facilities, 330 beds)
  • Regional Distribution:
  • South India: 7 Hospitals, 2 Heart Centres, 15 Clinics, 1 Diagnostic Centre, 2,159+132 beds
  • East India: 7 Hospitals, 3 Clinics, 1 Dialysis Centre, 2,121 beds
  • North India: 3 Hospitals, 838 beds
  • West India: 2 Hospitals, 374 beds
  • Total Staff: ~21,150 (Clinical: ~13,100, Non-clinical: ~8,050)

Clinical Highlights Q2 FY27

  • Narayana Institute of Cardiac Sciences, Bengaluru: Performed South India's first Percutaneous Transcatheter Tricuspid Valve Replacement (TTVR), India's first Transcatheter Tricuspid Valve Implantation on a 14-year-old, 54 TAVIs, 6 hybrid percutaneous pulmonary valve implantations, and record 38 cardiac surgeries in a single day.
  • NH Mumbai: Successfully managed complex surgical management of a newborn with sternal cleft.
  • NH RTIICS: Achieved multidisciplinary surgery for spindle cell sarcoma and robotic-assisted resection of Type B3 thymoma.

Financial Performance Q2 FY27

Consolidated Figures (₹ Mn):

  • Operating Revenue: ₹28,440 (↑73.0% YoY; ↑6.0% QoQ)
  • EBITDA: ₹6,054 (21.3% margin)
  • PAT: ₹3,012 (10.6% margin)
  • Total Comprehensive Income: ₹3,632

Segment Performance:

  • NH India: Revenue ₹14,402 Mn (↑16.6% YoY; ↑8.7% QoQ), EBITDA ₹3,548 Mn (24.6% margin), PAT ₹1,899 Mn (13.2% margin)
  • HCCI (Cayman): Revenue $63.4 Mn (↑28.2% YoY; ↑8.9% QoQ), EBITDA $22.1 Mn, PAT $16.6 Mn (26.2% margin)
  • NHUK: Revenue £64.4 Mn (↓0.9% QoQ), EBITDA £4.7 Mn (↓18.5% QoQ), PAT (£2.7) Mn

Balance Sheet (as of September 30, 2026):

  • Shareholder Equity: ₹50,054 Mn
  • Borrowings + Lease Liability: ₹60,753 Mn
  • Net Block + CWIP: ₹49,685 Mn
  • Goodwill: ₹14,133 Mn
  • Right to Use Assets: ₹9,596 Mn
  • Net Receivables: ₹9,619 Mn
  • Current Investments: ₹10,451 Mn
  • Cash and Bank Balance: ₹19,398 Mn

Net Debt Position:

  • India: Net Debt ₹8,501 Mn (Gross Debt ₹19,852 Mn, Cash ₹11,351 Mn)
  • Cayman Islands: Net Cash (₹6,781) Mn (Gross Debt ₹10,805 Mn, Cash ₹17,586 Mn)
  • United Kingdom: Net Debt ₹17,111 Mn (Gross Debt ₹18,991 Mn, Cash ₹1,880 Mn)
  • Consolidated Net Debt: ₹18,830 Mn (Net Debt to Equity Ratio: 0.38)
  • Foreign Currency Denominated Debt: US$114 Mn and GBP £150 Mn

India Operations Detail

Revenue Mix Q2 FY27:

  • Specialty Mix: Heart Centres, Oncology, Renal Sciences, Neuro Sciences, Orthopaedics, Others
  • Patient Type: Domestic Walk-in, Insured Patients, Schemes (CGHS, ESIS, etc.), International

Operational Metrics Q2 FY27:

  • Patient Footfalls: IP & OP figures shown graphically (exact numbers not quantified in disclosure)
  • ICU Occupied Bed Days: Shown graphically
  • ARPOB: ₹19.5 Mn (vs. ₹17.5 Mn in Q2 FY26)

Cost Structure India Hospitals:

  • Doctors and Nurses: 24.4%
  • Consumable Expenses: 19.0%
  • Other Expenses: 32.0%
  • EBITDA (excluding other income): 23.6% (Q1 FY27: 22.3%; Q2 FY26: 22.2%)

Insurance Business (NH Insurance) Q2 FY27

Financials (₹ Mn):

  • Gross Written Premium: 78 (vs. 70 Q2 FY26)
  • Net Written Premium: 75 (vs. 67 Q2 FY26)
  • Net Earned Premium: 133 (vs. 34 Q2 FY26)
  • Net Incurred Claims: 211 (vs. 25 Q2 FY26)
  • Profit After Tax: (151) (vs. (42) Q2 FY26)

Key Ratios:

  • Expense Ratio/NWP: 123% (vs. 97% Q2 FY26)
  • Claims Ratio/NEP: 159% (vs. 72% Q2 FY26)
  • Combined Operating Ratio: 282% (vs. 169% Q2 FY26)
  • Solvency Ratio: 162% (vs. 155% Q2 FY26)

International Operations

Cayman Islands (Q2 FY27):

  • Hospital Revenues and Insurance Revenues shown graphically
  • EBITDA of CIHL: US$ -1.1 Mn
  • Discharges & Out-Patients shown graphically
  • Inter-company elimination adjustment: US$2.7 Mn

United Kingdom (Q2 FY27):

  • EBITDA Post-IFRS: £4.7 Mn (Margin: 7.1%)
  • New center loss: GBP 0.8 Mn
  • One-time acquisition costs excluded from EBITDA

Expansion and Capex

  • Banashankari Hospital (South-West Bangalore) and Nagarabhavi Clinic commenced operations in the last week of September 2026; operating metrics will be reflected from Q3 FY27.
  • Capex strategy focused on "Building to strengthen our presence in flagship regions."

Digital Initiatives

  • Banashankari Digital Hospital implementation detailed with digital OP and IP journeys:
  • OP Journey: Paperless Registration, Touch-Free Consultation Invoicing, Counter-Free Service Invoicing, Live Queue Tracking, Green-Channel Pharmacy
  • IP Journey: Upfront Cost Estimate, One-Tap Digital Consent, Paperless Admission, Always-On IP Companion, Discharge Without Delay, Digital Gate Pass

ESG Initiatives

  • Renewable Electricity: 37% of total consumption (revised from 41% due to exclusion of one hospital)
  • Water Recycling: 39% of total consumption
  • Waste Management: 94% of biomedical waste treated

Shareholding Pattern

  • Total Number of Shares: 204,360,804 as of September 30, 2026
  • Key DIIs: Mirae Asset Management, Parag Parikh Asset Management, Nippon Life India Asset Management, Axis Asset Management, DSP Asset Management, Unifi Capital
  • Key FIIs: Vanguard Index Fund, Franklin Templeton Investment Funds, Simcah Partners LP, iShares by Blackrock, Government Pension Fund Global, Mirae Asset Fund

Forward-Looking Statements Disclaimer

The presentation contains forward-looking statements about business plans, strategy, future financial condition, growth prospects, and industry developments. Actual results may differ due to factors including business changes, competitive environment, and political, economic, legal and social conditions in India. This is not an offer to purchase shares.